Catalyst Health Solutions has appointed Timothy Pearson as chief financial officer (CFO) and executive vice president (EVP), effective 22 August 2011. Pearson currently serves as CFO and EVP of MedImmune, the global biologics business for AstraZeneca, where he has functional responsibility for finance, information technology, strategic planning and governance, and is a member of MedImmune’s executive team.
Pearson joined MedImmune in 1998 and prior to his promotion to CFO in 2007, was vice president (VP) of finance and treasurer with responsibility for treasury, corporate finance, tax, risk management, Sarbanes-Oxley (SOX) compliance, internal audit and equity plan administration. During his tenure at MedImmune, Pearson raised over US$1.6bn in debt and was a key leader in merger and acquisition (M&A) transactions and related post acquisition integration, including the US$500m acquisition of US Bioscience and the US$1.6bn acquisition of Aviron. Pearson is a founding officer and investment committee member of MedImmune Ventures and chairman of MedImmune’s business excellence team.
Pearson, a certified public accountant (CPA), holds dual BSc degrees in business administration from the University of Delaware and accounting from the University of Maryland, as well as an MSc degree in finance from Loyola University.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.